Niagen Bioscience, Inc.: updates and filings

NAGENASDAQBasic materials · Medicinal Chemicals & Botanical Products

Price

$1.81

November 20, 2026Market cap $145M

What Ploutos Investor adds for Niagen Bioscience

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 16 fiscal years, from FY2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 26% since Nov 4, 2026, when the 10-Q these figures come from was filed ($2.52 then, $1.87 on Nov 19, 2026). The figures date from before that move.10-Q
  • Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 76 daysAround Feb 4, 2027 · for Q4 2026

last Nov 4, 2026next Feb 4, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 4, 2026 latest annualNov 4, 2026 latest quarterly
  • Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 4, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Aug 4, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 4, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Jul 29, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 9, 2026Filing
    FormEFFECT
  • Jun 29, 2026Shareholder vote
    Form8-K
  • Jun 29, 2026Shelf registration for future offerings
    FormS-3
  • May 6, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • May 6, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 29, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 29, 2026Annual meeting proxy statement
    FormDEF 14A
  • Mar 19, 2026Other material events
    Form8-K
  • Mar 4, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Mar 4, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Feb 26, 2026Regulation FD disclosure, other material events
    Form8-K
  • Jan 30, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Dec 22, 2025Material agreement entered, Regulation FD disclosure
    Form8-K
  • Nov 6, 2025Other material events
    Form8-K
  • Nov 4, 2025Results of operations, Regulation FD disclosure
    Form8-K
  • Nov 4, 2025Quarterly reportfor the period to Sep 30, 2025
    Form10-Q
  • Oct 31, 2025Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Oct 6, 2025Regulation FD disclosure
    Form8-K
  • Aug 8, 2025Shares registered for employees
    FormS-8

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 18, 2007.

The full analysis

What do Niagen Bioscience's filings show?

The filings are where every one of Niagen Bioscience's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.